Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 4Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Ovarian Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Radiotherapy 41Cisplatin 36Fluorouracil 17Paclitaxel 15Docetaxel 14Cyclophosphamide 14Carboplatin 14Filgrastim 13Doxorubicin 13Gemcitabine 11Etoposide 11Capecitabine 10Surgical Procedures, Operative 9Methotrexate 9Leucovorin 9Chemotherapy, Adjuvant 9Vincristine 8Peripheral Blood Stem Cell Transplantation 8Oxaliplatin 8Dexamethasone 7Bevacizumab 7Topotecan 6Radiotherapy, Conformal 6Prednisone 6Fenretinide 6Cetuximab 6Neoadjuvant Therapy 5Mitomycin 5Irinotecan 5Ifosfamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × NETWORK × BCG Vaccine × Clear all
NCT00352079 2023-08-04

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Canadian Cancer Trials Group

Phase 3 Terminated
41 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00003386 2013-04-11

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

GOG Foundation

Phase 2 Terminated
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡